Asia Executives On The Move: EdiGene, Teijin, Astellas
Executive Summary
New round of funding allows EdiGene to hire a clinical development executive from Parexel, Teijin Pharma appoints a president, while Astellas has a new president of pharmaceutical technology.
You may also be interested in...
China mRNA Player Abogen Gets $300m More As Country Eyes Omicron Threat
From inactivated virus-based to mRNA platforms, the race is on in China to develop vaccines to fight the latest omicron variant, with substantial new funding pouring into one young mRNA company.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J’s pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna’s co-founder shares tips on innovation.
3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China
A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.